secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0001193125-21-309692
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma promotes Stephen Hill to COO effective Nov 1, 2021
---------------------------------------------------------------------

- Stephen Hill promoted from Chief Technical Operations Officer to Chief Operating Officer, effective November 1, 2021.
- Hill joined Lyell in June 2019; prior roles include SVP at AstraZeneca and VP at Amgen.
- New base salary of $485,000 with an annual bonus target of up to 55% of base salary.
- No family relationships with directors or executive officers; no arrangements with other persons.
- Employment is at-will; successor not appointed; no departure of any other officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/0001193125-21-309692-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312521309692/d250716d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-309692

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer